CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

LRX712Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D010003 Osteoarthritis, NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002758 Osteoarthritis HPO 0.50

There is one clinical trial.

Clinical Trials

1 A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis

This study will explore the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy will be evaluated in the context of the systemic safety and local tolerability of the investigational drug.

NCT04097379 Osteoarthritis (OA) Drug: LRX712 Drug: Placebo
MeSH:Osteoarthritis
HPO:Osteoarthritis

Primary Outcomes

Description: Efficacy of multiple intra-articular injections of LRX712 in regenerating cartilage as measured with 7T MRI

Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at week 28

Time: Baseline and Week 28

Secondary Outcomes

Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI

Measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at Week 16 and 52

Time: Baseline, Week 16 and 52

Description: Efficacy of multiple intra-articular injections of LRX712 measured with 7T MRI

Measure: Changes from baseline in cartilage morphometrics (volume and thickness) in the medial femoral condyle at Week 16, 28 and 52

Time: Baseline, Week 16, 28 and 52

Description: The observed time to reach max (Tmax) plasma concentration following drug administration

Measure: Time to Reach the Maximum Plasma Concentration (Tmax)

Time: Pre-dose to 28 weeks

Description: The observed maximum (Cmax) plasma concentration following drug administration

Measure: Maximum Observed Plasma Concentration (Cmax)

Time: Pre-dose to 28 weeks

Description: The observed minimum (Cmin) plasma concentration following drug administration

Measure: Minimum Observed Plasma Concentration (Cmin)

Time: Pre-dose to 28 weeks

Description: The observed synovial concentration following drug administration

Measure: Concentration in synovial fluid

Time: Day 1; week 4; week 8

Related HPO nodes (Using clinical trials)

HP:0002758: Osteoarthritis
Genes 86
CCN6 COL9A3 TNFRSF11B CCN6 ZNF687 COMP PHEX MATN3 TRPV4 COL2A1 SMAD3 F9 TRPS1 UFSP2 TRAPPC2 COL1A1 MEFV COL5A1 AIP COMP SLC40A1 ATP7B TGFB3 COL9A1 ACAN MATN3 ASPN FBN1 COL2A1 LMNA MMP13 CANT1 COL2A1 PHEX COL2A1 EXT2 COL2A1 COL2A1 GNAS AEBP1 COL2A1 CLCN7 COL5A2 FGFR3 ACAN F8 SCARB2 ANKH COL2A1 COL9A1 COL11A2 GDF5 GHR HLA-B COL11A2 COMP EXT1 TRPV4 COL9A3 TRAPPC2 ANKH COL11A1 COL5A1 UFSP2 ZMPSTE24 COL11A2 GBA COL1A1 LMX1B ACAN GPR101 COMP COL2A1 FRZB SLC26A2 COL9A2 KIF7 HPGD KIF22 SMAD3 CLCN7 COL3A1 MATN3 COL9A2 HGD MMP13
Protein Mutations 1
Q28D
SNP 0